Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of ...

A new study led by researchers at Wake Forest University School of Medicine and Atrium Health Levine Cancer has found that a ...

For decades, patients undergoing blood cancer treatment have been told to avoid certain foods to reduce infection risk, ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...